论文部分内容阅读
目的分析血清胃泌素释放前肽(Pro GRP)对小细胞肺癌(SCLC)的诊治和预后。方法收集512例肺癌患者的临床资料,选取同期健康体检者100例为对照组,采用电化学发光法检测肺癌患者及对照组血清Pro GRP水平,分析Pro GRP水平在肿瘤分期、治疗预后中的变化特点。结果 103例SCLC患者治疗前血清Pro GRP为(501.3±312.1)pg/ml,敏感性为82.5%,均高于非小细胞肺癌(NSCLC)组及对照组(P<0.05);SCLC患者随着病理分期的增加,Pro GRP水平显著增加,且敏感性也明显增加(P<0.05)。经化疗或手术等治疗后,治疗有效SCLC患者Pro GRP水平明显降低,病情无变化或进展缓慢者Pro GRP水平无明显下降甚至逐渐升高。结论血清Pro GRP对SCLC是一种特异性高的肿瘤标志物,可为临床治疗监测及其预后判断提供重要依据。
Objective To analyze the diagnosis, treatment and prognosis of small cell lung cancer (SCLC) by serum pro-gastrin (Pro GRP). Methods The clinical data of 512 patients with lung cancer were collected. 100 healthy subjects were selected as the control group. The level of Pro GRP in lung cancer patients and control group was detected by electrochemiluminescence. The changes of Pro GRP level in tumor stage and treatment prognosis Features. Results The serum Pro GRP in 103 SCLC patients before treatment was (501.3 ± 312.1) pg / ml, the sensitivity was 82.5%, which were higher than those in non-small cell lung cancer (NSCLC) group and control group (P <0.05) The pathological stage increased, Pro GRP level increased significantly, and the sensitivity also significantly increased (P <0.05). After treatment with chemotherapy or surgery, the level of Pro GRP in patients with active SCLC was significantly lower, and the level of Pro GRP was unchanged or even increased with no change or slow progression. Conclusion Serum Pro GRP is a highly specific tumor marker for SCLC, which may provide an important basis for clinical treatment monitoring and prognosis.